Display options
Cite
Tajima T, Fujieda K. Prenatal diagnosis and treatment of steroid 21-hydroxylase deficiency. Clin Pediatr Endocrinol. 2008;17(4):95-102doi: 10.1297/cpe.17.95.
Tajima, T., & Fujieda, K. (2008). Prenatal diagnosis and treatment of steroid 21-hydroxylase deficiency. Clinical pediatric endocrinology : case reports and clinical investigations : official journal of the Japanese Society for Pediatric Endocrinology, 17(4), 95-102. https://doi.org/10.1297/cpe.17.95
Tajima, Toshihiro, and Fujieda, Kenji. "Prenatal diagnosis and treatment of steroid 21-hydroxylase deficiency." Clinical pediatric endocrinology : case reports and clinical investigations : official journal of the Japanese Society for Pediatric Endocrinology vol. 17,4 (2008): 95-102. doi: https://doi.org/10.1297/cpe.17.95
Tajima T, Fujieda K. Prenatal diagnosis and treatment of steroid 21-hydroxylase deficiency. Clin Pediatr Endocrinol. 2008;17(4):95-102. doi: 10.1297/cpe.17.95. Epub 2008 Nov 18. PMID: 24790370; PMCID: PMC4004826.
Copy Download .nbib Format: NLM
Share it on

Clin Pediatr Endocrinol. 2008;17(4):95-102. doi: 10.1297/cpe.17.95. Epub 2008 Nov 18.

Prenatal diagnosis and treatment of steroid 21-hydroxylase deficiency.

Clinical pediatric endocrinology : case reports and clinical investigations : official journal of the Japanese Society for Pediatric Endocrinology

Toshihiro Tajima, Kenji Fujieda

Affiliations

  1. Department of Pediatrics, Hokkaido University School of Medicine, Sapporo, Japan.
  2. Department of Pediatrics, Asahikawa Medical College, Asahikawa, Japan.

PMID: 24790370 PMCID: PMC4004826 DOI: 10.1297/cpe.17.95

Abstract

Steroid 21-hydroxylase deficiency (21-OHD) accounts for 90-95% of congenital adrenal hyperplasia (CAH) cases. It is classified into three distinct clinical phenotypes: the salt-wasting (SW), simple virilizing (SV) and nonclassical forms (NC). As girls with the SW and SV forms of 21-OHD are exposed to high systemic levels of adrenal androgens during fetal life, they show genital ambiguity. To ameliorate the degree of genital virilization, prenatal dexamethasone treatment has been performed for more than two decades, although mainly in the USA and Europe. This treatment has proven to be effective in preventing or reducing genital virilization. Some data also show that prenatal diagnosis and treatment are safe for the mother and fetus. However, prenatal treatment is still controversial for the following reasons. First, the risk of having an affected female fetus is only one in eight when both parents are known carriers of the autosomal recessive trait. Therefore, seven of eight fetuses will receive dexamethasone unnecessarily, and this raises ethical questions. Furthermore, maternal side effects such as excessive weight gain and hypertension have been observed. Finally, the long-term safety and outcome for dexamethasone-exposed children have not been established. In Japan, prenatal diagnosis and treatment has rarely been reported because of these reasons. Therefore, we must be cautious, and this treatment should be carried out in special centers with the approval of their ethical committees, that are capable of performing chorionic villus sampling (CVS) and subsequently determining the karyotype and genotype of 21-OHD.

Keywords: dexamethasone; prenatal diagnosis; prenatal treatment; steroid 21-hydroxylase

References

  1. J Clin Endocrinol Metab. 2001 Dec;86(12):5651-7 - PubMed
  2. J Endocrinol. 2008 Feb;196(2):343-52 - PubMed
  3. Pediatr Res. 2007 Jan;61(1):111-6 - PubMed
  4. Proc Natl Acad Sci U S A. 1986 May;83(9):2841-5 - PubMed
  5. Lancet. 2005 Jun 18-24;365(9477):2125-36 - PubMed
  6. FASEB J. 1999 Jul;13(10):1185-94 - PubMed
  7. J Clin Endocrinol Metab. 2007 Feb;92(2):542-8 - PubMed
  8. J Clin Endocrinol Metab. 1993 Jul;77(1):86-9 - PubMed
  9. Nat Clin Pract Endocrinol Metab. 2007 May;3(5):405-13 - PubMed
  10. JAMA. 1997 Apr 2;277(13):1077-9 - PubMed
  11. J Clin Invest. 2007 Apr;117(4):1058-67 - PubMed
  12. Trends Endocrinol Metab. 2004 Oct;15(8):351-2 - PubMed
  13. J Biochem. 1991 Apr;109(4):638-44 - PubMed
  14. J Clin Endocrinol Metab. 1990 Apr;70(4):836-7 - PubMed
  15. N Engl J Med. 2003 Aug 21;349(8):776-88 - PubMed
  16. J Clin Endocrinol Metab. 1994 Feb;78(2):241-6 - PubMed
  17. Clin Chem. 2001 Jan;47(1):41-6 - PubMed
  18. J Clin Endocrinol Metab. 2002 Jul;87(7):3031-7 - PubMed
  19. J Clin Endocrinol Metab. 1992 Jul;75(1):249-53 - PubMed
  20. Am J Hum Genet. 1988 Jan;42(1):17-25 - PubMed
  21. Pediatr Res. 2001 Nov;50(5):563-4 - PubMed
  22. J Clin Invest. 1993 Nov;92(5):2182-90 - PubMed
  23. Endocr Dev. 2008;13:82-98 - PubMed
  24. Am J Obstet Gynecol. 1972 Jun 1;113(3):316-22 - PubMed
  25. Proc Natl Acad Sci U S A. 1995 Nov 7;92(23):10796-800 - PubMed
  26. Lancet. 1965 Sep 18;2(7412):553-5 - PubMed
  27. N Engl J Med. 2000 Nov 9;343(19):1362-8 - PubMed
  28. J Clin Endocrinol Metab. 1998 Nov;83(11):3872-80 - PubMed
  29. Proc Natl Acad Sci U S A. 1988 Oct;85(20):7486-90 - PubMed
  30. Endocr J. 1998 Jun;45(3):291-5 - PubMed
  31. J Clin Endocrinol Metab. 2004 Feb;89(2):610-4 - PubMed
  32. J Steroid Biochem Mol Biol. 1993 Apr;45(1-3):75-82 - PubMed
  33. Acta Paediatr. 1998 Feb;87(2):159-64 - PubMed
  34. Endocrinology. 2007 Apr;148(4):1813-22 - PubMed
  35. Ann N Y Acad Sci. 2004 Dec;1038:14-43 - PubMed
  36. J Urol. 1999 Aug;162(2):537-40 - PubMed

Publication Types